Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.68 |
| ▸ | ESR1 | P03372 | 6/20 | 0.68 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15717660 | 0.86 | ESR2 (0.71) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL21078370 | 0.84 | ESR1 (0.50) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL4450591 | 0.84 | ESR2 (0.74) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL12336908 | 0.81 | ESR2 (0.78) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL6932651 | 0.80 | ESR2 (0.57) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL15275550 | 0.80 | ESR2 (0.83) | ESR2ESR1MEN1KMT2ANPC1 | |
| SCHEMBL15137057 | 0.79 | NOS1 (0.55) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL15143942 | 0.79 | NOS1 (0.55) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL28859630 | 0.79 | MEN1 (0.73) | ESR2ESR1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL15137058 | 0.79 | NOS1 (0.55) | ESR2ESR1SLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777127-A | Chiral tetrahydro-beta-carboline derivative and preparation method and application thereof | 中山大学 | 2024-03-29 | — | — | CN | disclosed |
| US-20170305937-A1 | PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS | AMRI ITALY S.R.L. (IT) | 2017-10-26 | — | — | US | disclosed |
| US-20170305937-A1 | PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS | AMRI ITALY S.R.L. (IT) | 2017-10-26 | — | — | US | disclosed |
| US-9738663-B2 | Process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters | EUTICALS S.P.A. (IT) | 2017-08-22 | — | — | US | disclosed |
| US-9738663-B2 | Process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters | EUTICALS S.P.A. (IT) | 2017-08-22 | — | — | US | disclosed |
| EP-2994473-B1 | PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS | EUTICALS SPA (IT) | 2016-12-21 | — | — | EP | disclosed |
| US-20160075723-A1 | PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS | AMRI ITALY S.R.L. (IT) | 2016-03-17 | — | — | US | disclosed |
| EP-1988095-B1 | Method for manufacturing aminoaryl or heteroaryl boronic acid and their derivatives | EUTICALS GMBH (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2801577-A1 | Process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters | Euticals S.P.A. (IT) | 2014-11-12 | — | — | EP | disclosed |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2008103310-A1 | SUBSTITUTED FUSED-RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008103310-A1 | SUBSTITUTED FUSED-RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2007087443-A2 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20060243951-A1 | Electrochromic copolymer | ENERGY, U.S. DEPARTMENT OF | 2006-11-02 | — | — | US | disclosed |
| US-6867310-B1 | Arylation and vinylation of activated carbons | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6235871-B1 | Synthesis of oligoarylamines, and uses and reagents related thereto | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-05-22 | — | — | US | disclosed |
| WO-1999028290-A1 | SYNTHESIS OF OLIGOARYLAMINES, AND USES AND REAGENTS RELATED THERETO | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | ESR2 2384/4885ESR1 1431/4885SLC22A2 2037/4885 |
| US-20170305937-A1 | PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS | AADAT, BCAT2, BCAT1 | ESR2 1338/4885ESR1 1272/4885SLC22A2 1730/4885 |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | IL4, IL5, IL2 | ESR2 4013/4885ESR1 3400/4885SLC22A2 1413/4885 |
| US-20160075723-A1 | PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS | AADAT, BCAT2, BCAT1 | ESR2 2049/4885ESR1 1900/4885SLC22A2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.